B. Savoldo

H. Heslop, C. Rooney, N. Barshes, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

The Use of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus Induced Lymphoma in Transplant Recipients

H. Heslop, C. Rooney, B. Savoldo, 2000, Leukemia & lymphoma.

Utility of Safety Switch to Abrogate CD19.CAR T Cell-Associated Neurotoxicity.

J. Serody, A. Ivanova, J. Coghill, 2021, Blood.

Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.

C. Almici, A. Bonati, M. Rizzo, 1996, Blood.

Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity

J. Melenhorst, R. Krance, K. Leung, 2014, Clinical Cancer Research.

Changes in Chemokine Receptor Expression of Regulatory T Cells After Ex Vivo Culture

C. Rooney, B. Savoldo, G. Dotti, 2012, Journal of immunotherapy.

Fucosylation with Fucosyltransferase (FT)-VI or FT-VII Improves Cord Blood Engraftment

S. Parmar, E. Shpall, C. Bollard, 2014 .

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment.

K. Rezvani, S. Parmar, E. Shpall, 2014, Cytotherapy.

Reply to Sackstein

E. Shpall, C. Bollard, W. Decker, 2012 .

Noninvasive Bioluminescent Imaging Demonstrates Long‐Term Multilineage Engraftment of Ex Vivo‐Expanded CD34‐Selected Umbilical Cord Blood Cells

E. Shpall, C. Bollard, F. Marini, 2009, Stem cells.

Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.

C. Rooney, M. Brenner, B. Savoldo, 2001, Experimental hematology.

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.

H. Heslop, C. Rooney, M. Mims, 2008, Blood.

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).

H. Heslop, C. Rooney, F. Pane, 2008, Blood.

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma

S. Tuchman, C. Ramos, Aruna Mahendravada, 2019, Oncotarget.

T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

C. Rooney, A. Foster, D. Spencer, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma

F. Ligler, B. Savoldo, G. Dotti, 2021, Science advances.

Immunotherapy for Post‐Transplant Lymphoproliferative Disease

H. Heslop, C. Rooney, K. Straathof, 2002, British journal of haematology.

Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells.

M. Brenner, B. Savoldo, G. Dotti, 2002, Blood.

Transgenic expression of CD 40 ligand produces an in vivo antitumor immune response against both CD 40 and CD 40 plasmacytoma cells

M. Brenner, B. Savoldo, G. Dotti, 2002 .

Gene therapy to improve function of T cells for adoptive immunotherapy.

B. Savoldo, G. Dotti, C. Quintarelli, 2010, Methods in molecular biology.

In vitro elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or panitumumab

S. Ferrone, D. Lauro, A. Venditti, 2019, International journal of cancer.

Elimination of Egfr-Overexpressing Cancer Cells by CD32 Chimeric Receptor T Cells in Combination with Cetuximab or Panitumumab

S. Ferrone, D. Lauro, A. Venditti, 2019, bioRxiv.

Adoptive T-Cell Therapy for EBV-Associated Post-Transplant Lymphoproliferative Disease

H. Heslop, C. Rooney, C. Bollard, 2003, Acta Haematologica.

Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing

D. Cilloni, L. Mangoni, C. Carlo-Stella, 1999, Bone Marrow Transplantation.

A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor

B. Vincent, B. Savoldo, Yuhui Chen, 2019, Cancer Immunology Research.

Cellular Immunity to Epstein‐Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post‐Transplant Lymphoproliferative Disease

H. Heslop, C. Rooney, M. Finegold, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.

Zhensheng Liu, H. Heslop, C. Rooney, 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.

S. Colla, A. Levitzki, A. Gazit, 1999, Blood.

Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.

M. Vignetti, F. Mandelli, G. Meloni, 1997, Haematologica.

Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.

C. Rooney, P. Piedra, M. Brenner, 2004, Blood.

Fiber-modified Adenoviruses Generate Sub-group Cross-reactive, Adenovirus-specific Cytotoxic T Lymphocytes for Therapeutic Applications Short title: Adenovirus-specific, cytotoxic T lymphocytes for Immunotherapy purposes

C. Rooney, P. Piedra, M. Brenner, 2003 .

Selective Elimination of a Chemoresistant Side-Population of B-CLL Cells by Cytotoxic T Lymphocytes in Subjects Receiving an Autologous hCD40L/IL-2 Tumor Vaccine

H. Heslop, M. Goodell, E. Yvon, 2009, Leukemia.

Shc Overexpression Induces Selective Hypersensitivity to GM-CSF and Prevents Apoptosis of the GM-CSF-Dependent Acute Myelogenous Leukemia Cell Line GF-D8

T. Barbui, P. Pelicci, C. Carlo-Stella, 1998 .

Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.

H. Heslop, C. Rooney, B. Savoldo, 2004, Best practice & research. Clinical haematology.

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma

S. Tuchman, C. Ramos, Aruna Mahendravada, 2019, Oncotarget.

Inducible apoptosis as a safety switch for adoptive cell therapy.

Adrian P Gee, Helen E Heslop, Cliona M Rooney, 2011, The New England journal of medicine.

infusion of T cells expressing the inducible caspase 9 safety transgene Long-term outcome after haploidentical stem cell transplant and

R. Krance, C. Martinez, Hao Liu, 2014 .

Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients

B. Savoldo, D. Pagliara, 2012, Current opinion in infectious diseases.

GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision

B. Savoldo, Yuhui Chen, G. Dotti, 2020, Nature Cancer.

Posttransplant lymphoproliferative diseases.

B. Savoldo, T. Gross, A. Punnett, 2010, Pediatric clinics of North America.

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

P. Hanley, C. Cruz, Hao Liu, 2009, Blood.

Plasma Markers of B-Cell Activation and Clonality in Pediatric Liver and Hematopoietic Stem Cell Transplant Recipients

R. Pfeiffer, H. Heslop, A. Zingone, 2013, Transplantation.

Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high‐risk for EBV infection

H. Heslop, C. Rooney, N. Barshes, 2006, Clinical transplantation.

Use of cytokine polymorphisms and Epstein–Barr virus viral load to predict development of post‐transplant lymphoproliferative disorder in paediatric liver transplant recipients

H. Heslop, C. Rooney, N. Barshes, 2006, Clinical transplantation.

Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β

Christopher A. Lazarski, C. Cruz, C. Bollard, 2022, Molecular therapy. Methods & clinical development.

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens

C. Rossig, H. Juergens, B. Savoldo, 2012, Cancer Immunology, Immunotherapy.

CD30‐CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL)

H. Heslop, C. Rooney, C. Ramos, 2018, Hematological Oncology.

adenovirus-specific cytotoxic T lymphocytes for therapeutic applications Fiber-modified adenoviruses generate sub-group cross-reactive,

C. Rooney, P. Piedra, M. Brenner, 2013 .

Correction: Interleukin-7 Mediates Selective Expansion of Tumor-Redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-Cell Inhibition

M. Brenner, Aruna Mahendravada, B. Savoldo, 2014, Clinical Cancer Research.

Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells

D. Cilloni, A. Tabilio, C. Carlo-Stella, 1998, Leukemia.

Selective expression and constitutive phosphorylation of Src-homology-2 and collagen-homology domains proteins in the CD34+ fraction of chronic myelogenous leukemias

P. Pelicci, P. Lunghi, A. Tabilio, 2000 .

Gene Transfer of IL-7R alpha (IL-7Rα) on Antigen-Specific Cytotoxic T Cells (CTLs) Restores Their Ability To Respond to IL-7 Cytokine.

H. Heslop, C. Rooney, M. Brenner, 2007 .

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

Tali Raveh-Sadka, Xin Xu, Nisha Ghatwai, 2020, Nature Medicine.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Hao Liu, H. Heslop, C. Rooney, 2008, Nature Medicine.

Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes

Sara R. Selitsky, J. Parker, S. Selitsky, 2019, Cancer Immunology Research.

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

J. Serody, A. Ivanova, B. Savoldo, 2021, Blood.

Infusion of CD30 CAR T Cells Is Safe and Effective As Consolidation Following Autologous Hematopoietic Stem Cell Transplant

J. Serody, A. Ivanova, T. Shea, 2021, Transplantation and Cellular Therapy.

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

C. Cruz, S. Lam, R. Krance, 2013, Blood.

Interleukin-23 engineering improves CAR T cell function in solid tumors

B. Vincent, P. Shou, B. Savoldo, 2020, Nature Biotechnology.

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

Hao Liu, L. Bouchier-Hayes, I. Caruana, 2014, Cancer research.

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

U. Olsson‐Strömberg, M. Jarvius, B. Savoldo, 2015, PloS one.

Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.

H. Heslop, G. Bauer, P. Marks, 2021, Blood cancer discovery.

C. Creighton, Hao Liu, H. Heslop, 2014, Blood.

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling

Hao Liu, H. Heslop, C. Rooney, 2016 .

Design and development of therapies using chimeric antigen receptor‐expressing T cells

S. Gottschalk, M. Brenner, B. Savoldo, 2014, Immunological reviews.

Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

R. Gilbertson, H. Heslop, C. Rooney, 2007, Cancer research.

Gene therapy for the treatment of cancer: From laboratory to bedside

C. Ramos, B. Savoldo, G. Dotti, 2015 .

B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres

Jeffrey S. Damrauer, G. Finocchiaro, B. Pollo, 2019, EBioMedicine.

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.

L. Naldini, M. Marcatti, C. Bordignon, 2013, Blood.

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

Tali Raveh-Sadka, Bin Liu, Nisha Ghatwai, 2020, Nature Medicine.

317 ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density

D. Irvine, M. Papotti, C. Voena, 2022, Regular and Young Investigator Award Abstracts.

Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.

T. Pierson, J. Cohen, P. Burbelo, 2009, Virology.

PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation.

Songbin Fu, Xiongbin Lu, Xia Lin, 2009, Cellular signalling.

Adoptive T cell therapy: Boosting the immune system to fight cancer.

B. Savoldo, R. Ranganathan, Ernesto Leon, 2020, Seminars in immunology.

Strategies to Enhance Migration and Persistence of Chimeric Antigen Receptor (CAR)-T Cells into Tumors

B. Savoldo, Yuhui Chen, G. Dotti, 2016 .

Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells

M. Del Vecchio, A. Anichini, E. Yvon, 2009, Clinical Cancer Research.

Cancer Therapy : Preclinical Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD 2-Specific T cells

A. Anichini, E. Yvon, M. Brenner, 2009 .

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

S. Parmar, G. Garcia-Manero, E. Shpall, 2014, Cytotherapy.

Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies

E. Sturgis, Matthew L. Anderson, U. Gerdemann, 2013, Journal of immunotherapy.

Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells

Sung Hyun Lee, T. Kafri, Yajing Hao, 2022, bioRxiv.

Challenges of driving CD30-directed CAR-T cells to the clinic

B. Savoldo, N. Grover, 2019, BMC Cancer.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

H. Heslop, C. Rooney, H. Abken, 2007, Blood.

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

H. Heslop, C. Rooney, C. Ramos, 2015, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.

Hao Liu, H. Heslop, C. Rooney, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Hao Liu, H. Heslop, C. Rooney, 2016, The Journal of clinical investigation.

Glycolysis determines dichotomous regulation of T cell subsets in hypoxia.

J. Neilson, J. Rodgers, J. Yustein, 2016, The Journal of clinical investigation.

Genetic modification of human T lymphocytes for the treatment of hematologic malignancies

B. Savoldo, G. Dotti, V. Hoyos, 2012, Haematologica.

Interleukin-23 engineering improves CAR T cell function in solid tumors

B. Vincent, P. Shou, B. Savoldo, 2020, Nature Biotechnology.

K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo

I. Caruana, G. Weber, B. Savoldo, 2015, Clinical Cancer Research.

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.

Hao Liu, S. Kenney, S. Gottschalk, 2011, Blood.

CARs on track in the clinic.

S. Rosenberg, M. Sadelain, C. June, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

S. Ferrone, L. Su, P. Shou, 2021, Clinical Cancer Research.

Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication

L. Naldini, C. Bordignon, F. Ciceri, 2012 .

Survivin-specific T cell receptor targets tumor but not T cells.

H. Heslop, P. Barth, B. Savoldo, 2015, The Journal of clinical investigation.

Repetitive Noninvasive Monitoring of HSV1-tk-Expressing T Cells Intravenously Infused into Nonhuman Primates Using Positron Emission Tomography and Computed Tomography with 18F-FEAU

O. Mawlawi, E. Shpall, C. Bollard, 2009, Molecular imaging.

Treating hematological malignancies with cell therapy: where are we now?

B. Savoldo, Elisa Landoni, 2018, Expert opinion on biological therapy.

Cancer battlefield: six characters in search of an author.

B. Savoldo, L. Huye, 2012, Immunotherapy.

CD 44 v 6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

L. Naldini, M. Marcatti, C. Bordignon, 2013 .

Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals1

Zhensheng Liu, H. Heslop, C. Rooney, 2002, The Journal of Immunology.

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

M. Ponzoni, A. Biondi, B. Savoldo, 2011, Blood.

Chimeric Antigen Receptors for Cancer Immunotherapy.

B. Savoldo, G. Dotti, Claudia Geldres, 2016, Methods in molecular biology.

High throughput quantitative reverse transcription PCR assays revealing over‐expression of cancer testis antigen genes in multiple myeloma stem cell‐like side population cells

C. Chang, Y. Zu, J. Wen, 2014, British journal of haematology.

Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease

Helen E. Heslop, Cliona M. Rooney, Juan F. Vera, 2013, Haematologica.

What influence has B-cell depletion on viral infections?

C. Rooney, B. Savoldo, A. Kaka, 2007, Leukemia & lymphoma.

Gene therapy to improve migration of T cells to the tumor site.

B. Savoldo, B. De Angelis, A. Di Stasi, 2010, Methods in molecular biology.

ADVANCES IN LLM

B. Savoldo, 2021 .

Response: To force the expression of CCR4 and/or of CCR5 chemokine receptor in T cells for immunotherapy of Hodgkin lymphoma: that is the question

B. Savoldo, G. Dotti, 2010 .

Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas

Hao Liu, H. Heslop, C. Rooney, 2015 .

A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+ Lymphomas

J. Serody, A. Ivanova, T. Shea, 2019, Biology of Blood and Marrow Transplantation.

CARs on Track in the Clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy Washington DC, 18 May 2010.

S. Rosenberg, M. Sadelain, C. June, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

J. Serody, A. Ivanova, T. Shea, 2018, Blood.

A phase 1b/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma.

J. Serody, A. Ivanova, T. Shea, 2017 .

Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias.

P. Pelicci, P. Lunghi, A. Tabilio, 2000, Cancer research.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

J. Orange, R. Başar, K. Rezvani, 2018, Leukemia.

Abstract A041: CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia – report from the Swedish phase I/IIa trial

M. Höglund, M. Essand, M. Brenner, 2016 .

748. A Clinical Trial Using Third Generation CD19 Targeting CAR T Cells for Relapsed Lymphoma and Leukemia

M. Höglund, M. Essand, M. Brenner, 2016 .

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

H. Heslop, C. Rooney, C. Ramos, 2015, Blood.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Hao Liu, H. Heslop, C. Rooney, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Hao Liu, H. Heslop, C. Rooney, 2011, Blood.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

H. Heslop, C. Rooney, H. Abken, 2007, Blood.

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.

Hao Liu, S. Kenney, S. Gottschalk, 2011, Blood.

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

B. Savoldo, Chuang Sun, G. Dotti, 2016, Blood.

Gene therapy for the treatment of cancer: From laboratory to bedside

B. Savoldo, G. Dotti, Carlos A. Ramos, 2008 .

Building safety into CAR-T therapy

B. Savoldo, N. Grover, Daniel T Peters, 2023, Human vaccines & immunotherapeutics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

S. Parmar, G. Garcia-Manero, E. Shpall, 2014, Cytotherapy.

Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.

Zhensheng Liu, T. Okamura, C. Rooney, 2002, Blood.

Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R γ null (NSG) mice

E. Shpall, C. Bollard, B. Savoldo, 2012 .